Company Description
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases.
Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib.
The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020.
Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Mar 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | Andrew Robbins |
Contact Details
Address: 275 Wyman Street, 3rd Floor Waltham, Massachusetts 02451 United States | |
| Phone | 617 945 5576 |
| Website | cogentbio.com |
Stock Details
| Ticker Symbol | COGT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001622229 |
| CUSIP Number | 19240Q201 |
| ISIN Number | US19240Q2012 |
| Employer ID | 46-5308248 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew R. Robbins M.B.A. | President, Chief Executive Officer and Director |
| Dr. John Edward Robinson Ph.D. | Chief Scientific Officer |
| Dr. Jessica Sachs M.D. | Chief Medical Officer |
| John L. Green C.A., CPA | Chief Financial Officer and Principal Accounting Officer |
| Brad Barnett | Chief Technology Officer |
| Christi Waarich | Senior Director of Investor Relations |
| Evan D. Kearns J.D. | Chief Legal Officer and Corporate Secretary |
| Erin Schellhammer | Chief People Officer |
| Dana R. Martin Pharm.D. | Senior Vice President of Medical Affairs and Chief Patient Officer |
| Brad Fell | Senior Vice President of Chemistry |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 9, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |